Parkman Healthcare Partners’s Idexx Laboratories IDXX Stock Holding History

Parkman Healthcare Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,000	Closed	-$8.43M	–	88
2026 Q1	$8.43M	Buy	+15,000	New	+$9.62M	0.87%	44
2022 Q2	–	Sell	-9,388	Closed	-$5.14M	–	83
2022 Q1	$5.14M	Sell	9,388 -1,582	-14%	-$832K	1.5%	26
2021 Q4	$7.22M	Buy	10,970 +3,303	+43%	+$2.07M	1.59%	25
2021 Q3	$4.77M	Hold	7,667	–	–	1.21%	25
2021 Q2	$4.84M	Buy	7,667 +35	+0.5%	+$19.3K	1.06%	36
2021 Q1	$3.73M	Buy	7,632 +39	+0.5%	+$19.5K	0.87%	39
2020 Q4	$3.8M	Buy	7,593 +93	+1%	+$41.6K	0.97%	43
2020 Q3	$2.95M	Buy	+7,500	New	+$2.77M	0.78%	45

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Parkman Healthcare Partners's IDXX Position: Q2 2026 in Review

Parkman Healthcare Partners sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 15,000 shares — an estimated $8.43M sold.

Parkman Healthcare Partners first reported a position in IDXX in Q3 2020 and held it in 8 quarters. The position peaked at $8.43M in Q1 2026. 1,300 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Parkman Healthcare Partners reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
Parkman Healthcare Partners sold 15,000 Idexx Laboratories shares in Q2 2026, an estimated $8.43M.
Parkman Healthcare Partners first reported a position in Idexx Laboratories in Q3 2020 and held it in 8 quarters.
Parkman Healthcare Partners's Idexx Laboratories position peaked at $8.43M in Q1 2026.
1,300 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.